Combination antiretroviral therapy (cART) has significantly reduced HIV-related morbidity and mortality; however, residual inflammation often persists in the absence of detectable viral load. In addition, chronic use of cART and an ageing HIV-positive population present new challenges to treating physicians who must balance the need for good virological control with risk of treatment-related toxicities. Discussions at the 17th International Workshop on Co-morbidities and AdverseDrug Reactions in HIV once again sought a better understanding of the complex relationship between HIV-, treatment- and age-related factors in the development of comorbidities in those infected with HIV. Key data from the meeting pertaining to inflammatory pathways in HIV, adipose tissue metabolism, cardiovascular disease, bone health, ageing and frailty, neurocognitive dysfunction, pulmonary disease and HCV coinfection are the focus of this report.
References
1.
HsueP.Y., DeeksS.G., HuntP.W.Immunologic basis of cardiovascular disease in HIV-infected adults.J Infect Dis2012; 205Suppl 3: S375–S382.
2.
ChungH.Y., CesariM., AntonS.Molecular inflammation: underpinnings of aging and age-related diseases.Ageing Res Rev2009; 8: 18–30.
3.
WarrinerA.H., BurkholderG.A., OvertonE.T.HIV-related metabolic comorbidities in the current ART era.Infect Dis Clin North Am2014; 28: 457–476.
4.
PathaiS., BajillanH., LandayA.L., HighK.P.Is HIV a model of accelerated or accentuated aging?J Gerontol A Biol Sci Med Sci2014; 69: 833–842.
5.
GreeneW.C.Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
6.
MonroeK.M., YangZ., JohnsonJ.R.IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV.Science2014; 343: 428–432.
7.
DoitshG., GallowayN.L., GengX.Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.Nature2014; 505: 509–514.
8.
TagerA.Organ fibrosis: a major cause of co-morbidity in HIV infection.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
9.
WynnT.A., RamalingamT.R.Mechanisms of fibrosis: therapeutic translation for fibrotic disease.Nat Med2012; 18: 1028–1040.
10.
EstesJ.D., WietgrefeS., SchackerT.Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection.J Infect Dis2007; 195: 551–561.
11.
ZengM., SmithA.J., WietgrefeS.W.Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections.J Clin Invest2011; 121: 998–1008.
12.
SchackerT.W., ReillyC., BeilmanG.J.Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count.AIDS2005; 19: 2169–2171.
13.
EstesJ.D., ReillyC., TrubeyC.M.Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.J Infect Dis2015; 211: 744–754.
14.
DuffieldJ.S., LupherM., ThannickalV.J., WynnT.A.Host responses in tissue repair and fibrosis.Annu Rev Pathol2013; 8: 241–276.
ChenJ.Y., FeeneyE.R., ChungR.T.HCV and HIV co-infection: mechanisms and management.Nat Rev Gastroenterol Hepatol2014; 11: 362–371.
18.
OvertonE.T.The interplay of atherosclerosis and inflammation.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
19.
BoccaraF., LangS., MeulemanC.HIV and coronary heart disease: time for a better understanding.J Am Coll Cardiol2013; 61: 511–523.
20.
CaronM., AuclairM., SterlingotH., KornprobstM., CapeauJ.Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.AIDS2003; 17: 2437–2444.
21.
HreskoR.C., HruzP.W.HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4.PLoS ONE2011; 6: e25237.
22.
LeroyerS., VatierC., KadiriS.Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.J Lipid Res2011; 52: 207–220.
23.
FeeneyE.R., van VonderenM.G., WitF.Zidovudine/ lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.AIDS2012; 26: 2165–2174.
24.
HaubrichR.H., RiddlerS.A., DiRienzoA.G.Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.AIDS2009; 23: 1109–1118.
25.
MaughanR.T., MallonP.W.Lopinavir alone and ritonavir-boosted lopinavir induces adipocyte toxicity at nanomolar concentrations in vitro.Antivir Ther2015; 20Suppl 1: A16.
26.
VillarroyaF.The role of adipose tissue in HIV-infected patients.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
27.
Díaz-DelfínJ., DomingoP., WabitschM., GiraltM., VillarroyaF.HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes.Antivir Ther2012; 17: 529–540.
28.
GuallarJ.P., Gallego-EscuredoJ.M., DomingoJ.C.Differential gene expression indicates that ‘buffalo hump’ is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy.AIDS2008; 22: 575–584.
29.
LinZ., TianH., LamK.S.Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.Cell Metab2013; 17: 779–789.
30.
ReedsD.N., ChambersK.T., DunnR.J., YarasheskiK.E., FinckB.N.Tauroursodeoxycholic acid lowers intrahepatic triglyceride content and improves liver function tests and plasma lipid profile in insulin-resistant, HIV+ people receiving ritonavir.Antivir Ther2015; 20Suppl 1: A17.
31.
YangJ.S., KimJ.T., JeonJ.Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.PLoS ONE2010; 5: e13858.
32.
FabbriniE., MagkosF., MohammedB.S.Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.Proc Natl Acad Sci U S A2009; 106: 15430–15435.
33.
RappoccioloG., JaisM., PiazzaP.Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors.MBio2014; 5: e01031–13.
34.
RappoccioloG., MartinsonJ., CampbellD., McGowanM., GuptaP., RinaldoC.Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4+ T cells in non-progressors.Antivir Ther2015; 20Suppl 1: A7.
35.
ErlandsonK.M., LiX., AbrahamA.Long-term impact of HIV wasting on physical function in the Multicenter AIDS Cohort Study.Antivir Ther2015; 20Suppl 1: A14.
36.
GrantP.M., KitchD., McComseyG.Long-term body composition changes in antiretroviral-treated HIV-infected individuals.Antivir Ther2015; 20Suppl 1: A18.
37.
LakeJ.E., LiX., PalellaF.J.Jr.Metabolic health across the body mass index spectrum in HIV-infected and HIV-uninfected men.Antivir Ther2015; 20Suppl 1: A10.
38.
MorlatP., RoussillonC., HenardS.Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.AIDS2014; 28: 1181–1191.
39.
FreibergM.S., ChangC.C., KullerL.H.HIV infection and the risk of acute myocardial infarction.JAMA Intern Med2013; 173: 614–622.
40.
YarasheskiK.E., LacinyE., OvertonE.T.18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors.J Inflamm (Lond)2012; 9: 26.
41.
van ZoestR.Increased prevalence of hypertension in HIV-infected patients, most with suppressed viraemia on combination antiretroviral therapy, is associated with changes in body composition.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
42.
DonatoA.J., PierceG.L., LesniewskiL.A., SealsD.R.Role of NFkappaB in age-related vascular endothelial dysfunction in humans.Aging (Albany NY)2009; 1: 678–680.
43.
AuclairM., AfonsoP., Caron-DebarleM., CapeauJ.Impact of maraviroc, dolutegravir and darunavir/ritonavir on human coronary endothelial cells functions according to age.Antivir Ther2015; 20Suppl 1: A11.
44.
RiddlerS.A., LiX., ChuH.Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.HIV Med2007; 8: 280–287.
45.
DuprezD.A., KullerL.H., TracyR.Lipoprotein particle subclasses, cardiovascular disease and HIV infection.Atherosclerosis2009; 207: 524–529.
46.
DubéM.P., KomarowL., FichtenbaumC.J.Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: effects on endothelial function, lipoproteins, and inflammation.Clin Infect Dis2015; 61: 840–849.
SabinC.A., WormS.W., WeberR.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.Lancet2008; 371: 1417–1426.
49.
WangX., ChaiH., LinP.H., YaoQ., ChenC.Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.Am J Pathol2009; 174: 771–781.
50.
OrdenS., HernándezC., de PabloC.Abacavir does not produce vascular inflammatory effects in ATP receptor-deficient mice.Antivir Ther2015; 20Suppl 1: A12.
51.
BoccaraF., Mary-KrauseM., TeigerE.Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis.Eur Heart J2011; 32: 41–50.
52.
BoccaraF., Hauguel-MoreauM., SilvainJ.HIV-infected patients exert higher residual platelet reactivity on DAPT compared to controls after acute coronary syndrome.Antivir Ther2015; 20Suppl 1: A23.
53.
Serrano-VillarS., MorenoS., Fuentes-FerrerM.The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery.HIV Med2014; 15: 40–49.
54.
Serrano-VillarS., SainzT., LeeS.A.HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.PLoS Pathog2014; 10: e1004078.
55.
YounesS-A, FreemanM.L., MuddJ.C.IL-15 and CMV co-infection drive CD8 T-cell expansion in HIV-1 infection.Antivir Ther2015; 20Suppl 1: A8.
56.
FreemanM.L., MuddJ.C., SounesS.A.CD8 T-cells expressing the fractalkine (endothelial homing) receptor CX3CR1 in treated HIV infection are promoted by CMV co-infection and functionally impaired by platelet interactions.Antivir Ther2015; 20Suppl 1: A8.
57.
FadiniG.P., AvogaroA.Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond.Atherosclerosis2013; 229: 23–29.
58.
YarasheskiK.E., WangW., HeH.Sitagliptin increases the active form of stromal derived factor-1 alpha (SDF1α 1-67) correlates with an increase in endothelial progenitor cell number in HIV+ adults with impaired glucose tolerance.Antivir Ther2015; 20Suppl 1: A9.
59.
BrownT.T., QaqishR.B.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS2006; 20: 2165–2174.
60.
CotterA.G., SabinC.A., SimelaneS.Relative contribution of HIV infection, demographics and body mass index to bone mineral density.AIDS2014; 28: 2051–2060.
61.
ReyD., TregerM., SibiliaJ.Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.Infect Dis (Lond)2015; 47: 88–95.
62.
MuellerN.J., FuxC.A., LedergerberB.High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients.AIDS2010; 24: 1127–1134.
63.
SlamaL., ReddyS., PaellaF.J.Jr., PialouxG., PhairJ., BrownT.T.Changes in bone turnover markers with HIV seroconversion and antiretroviral therapy initiation.Antivir Ther2015; 20Suppl 1: A18.
64.
HoyJ.F., GrindB., RoedigerM.Effects of immediate versus deferred initiation of antiretroviral therapy on bone mineral density: a substudy of the INSIGHT Strategic Timing of Antiretroviral (START) study.Antivir Ther2015; 20Suppl 1: A25.
65.
MartinezE., MonteriroP., Del RioL.Role of antiretroviral therapy on bone mass and bone texture.Antivir Ther2015; 20Suppl 1: A20.
66.
IkiM., TamakiJ., KadowakiE.Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study.J Bone Miner Res2014; 29: 399–407.
67.
AlvarezE., CotterA.G., SabinC.Assessment of associations between markers of renal function and bone mineral density in HIV-positive and HIV-negative subjects.Antivir Ther2015; 20Suppl 1: A74.
68.
YinM.T., ShiauS., SteehlauR.Decreased bone mass in perinatally HIV-infected school-aged South African children on antiretrovirals.Antivir Ther2015; 20Suppl 1: A21.
69.
GrantR.M., AndersonP.L., McMahanV.Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.Lancet Infect Dis2014; 14: 820–829.
70.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA2004; 292: 191–201.
71.
MulliganK., GliddenD.V., AndersonP.L.Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial.Clin Infect Dis2015; 61: 572–580.
72.
MulliganK., RutledgeB., ApogiannisB.G.Bone changes in young men ages 18–22 enrolled in a pre-exposure prophylaxis (PrEP) safety and demonstration study using tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).Antivir Ther2015; 20Suppl 1: A21.
73.
SmitM., BrinkmanK., GeerlingsS.Future challenges for clinical care of an ageing population infected with HIV: a modelling study.Lancet Infect Dis2015; 15: 810–818.
74.
VillarroyaJ., Gallego-EscuredoJ.M., MoureR.HIV-1 infection is associated with aging-related alterations in systemic parameters and adipose tissue molecular signature.Antivir Ther2015; 20Suppl 1: A14.
75.
AlthoffK.N., JacobsonL.P., CranstonR.D.Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men.J Gerontol A Biol Sci Med Sci2014; 69: 189–198.
76.
ÖnenN.F., OvertonE.T.A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging.Curr Aging Sci2011; 4: 33–41.
77.
KooijK.W., WitF.W., van ZoestR.A.Frailty predicts all-cause mortality, hospital admission and falls in HIV-infected and uninfected middle-aged individuals.Antivir Ther2015; 20Suppl 1: A24.
78.
CesariM.Frailty: concept and clinical consequences.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
79.
StudenskiS., PereraS., PatelK.Gait speed and survival in older adults.JAMA2011; 305: 50–58.
80.
KunisakiK.M.Will expanded ART use reduce the burden of HIV-associated chronic lung disease?Curr Opin HIV AIDS2014; 9: 27–33.
81.
KunisakiK.M., NiewoehnerD.E., ColinsG.Lung function decline in HIV: effects of immediate versus deferred ART treatment on lung function decline in a multisite, international, randomized controlled trial.Antivir Ther2015; 20Suppl 1: A22.
82.
FitzpatrickM.E., SinghV., BertoletM.Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort.AIDS2014; 28: 2505–2515.
83.
FitzpatrickM.E., BertoletM., KessingerC.Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease: a randomized pilot study.Antivir Ther2015; 20Suppl 1: A15.
84.
KinlayS., SchwartzG.G., OlssonA.G.High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.Circulation2003; 108: 1560–1566.
Arenas-PintoA., StöhrW., GodiC.Neuroimaging findings in effectively suppressed HIV+ patients with symptomatic neurocognitive dysfunction: a cross-sectional sub-study from the PIVOT Trial.Antivir Ther2015; 20Suppl 1: A5.
87.
CacoubP.Revisiting extrahepatic manifestations of HCV: from immune- to inflammatory-related manifestations.17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. 20–22 October 2015, Barcelona, Spain.
88.
LeeM.H., YangH.I., LuS.N.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.J Infect Dis2012; 206: 469–477.
89.
CacoubP., GragnaniL., ComarmondC., ZignegoA.L.Extrahepatic manifestations of chronic hepatitis C virus infection.Dig Liver Dis2014; 46Suppl 5: S165–S173.
90.
CacoubP., RatziuV., MyersR.P.Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C.J Hepatol2002; 36: 812–818.
91.
ByrnesV., MillerA., LowryD.Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.J Hepatol2012; 56: 549–556.
92.
YounossiZ., StepanovaM., BronowickiJ-P, CarrieriP., BourlieM.The impact of ledipasvir (ldv)/sofosbuvir (sof) combination on health-related quality of life (hrql) and patient-reported outcomes (pros) in cirrhotic patients with chronic hepatitis c (ch-c): the Sirius Study.J Hepatol2015; 62Suppl 2: P0713.
93.
YounossiZ.M., StepanovaM., SulkowskiM.Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes.J Infect Dis2015; 212: 367–377.
94.
PettaS., MaidaM., MacalusoF.S.Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies.Gastroenterology2016; 150: 145–155.
95.
HsuC.S., KaoJ.H., ChaoY.C.Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.Aliment Pharmacol Ther2013; 38: 415–423.
96.
MaruyamaS., KodaM., OyakeN.Myocardial injury in patients with chronic hepatitis C infection.J Hepatol2013; 58: 11–15.
97.
RoccatelloD., BaldovinoS., RossiD.Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.Nephrol Dial Transplant2004; 19: 3054–3061.
98.
SaadounD., ThibaultV., PialouxG.All oral therapy (sofosbuvir-ribavirin) combination in severe HCV-mixed cryoglobulinemia vasculitis, the vascuvaldic study.J Hepatol2015; 62Suppl 2: P0813.
99.
SorianoV., VispoE., Fernandez-MonteroJ.V., LabargaP., BarreiroP.Update on HIV/HCV coinfection.Curr HIV/ AIDS Rep2013; 10: 226–234.
100.
ScherzerR., HeymsfieldS.B., RimlandD.Association of serum albumin and AST with 5-year all-cause mortality in HIV/HCV coinfection and HIV monoinfection.Antivir Ther2015; 20Suppl 1: A4.
101.
De LucaA., LorenziniP., CastagnaA.Active HCV replication is associated with incident and prevalent type 2 diabetes in persons living with HIV.Antivir Ther2015; 20Suppl 1: A3.
102.
MaussS., BergerF., IngilizP.Differential effects of HCV therapy with direct- acting antiviral agents on lipids in the German multicenter cohort on direct antiviral agents in HCV- and HIV/HCV-infected patients (GECCO).Antivir Ther2015; 20Suppl 1: A4.
